clinical trial · NCT04203693
Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
Almirall, S.A.·—·completed·n = 331
Plaque PsoriasisTildrakizumab
brief summary
The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.
started
Oct 30, 2019
primary completion
May 2, 2024
completion
May 2, 2024
last updated
Mar 2, 2026
official title
Observational Study to Assess the Effectiveness, Safety Profile and Real-life Prescribing and Utilization Patterns of Tildrakizumab (Ilumetri®) in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice. (SAIL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol